No Data
No Data
With a compound annual growth rate of only 2.6% over the past five years, China's top 100 pharmaceutical companies are entering an adjustment period. How will the industry break through under internal and external pressures?
According to the data from China Meheco Group, in 2023, multiple operation indicators of the pharmaceutical industry's leading companies have declined. The compound annual growth rate of the top 100 pharmaceutical companies in the country in the past five years is only 2.6%, and the industry as a whole has entered the adjustment phase from the initial high-speed growth. Behind the weak growth, the health industry is also undergoing transformation: overseas licensing trades for innovative drugs have reached a new high, and leading companies are accelerating outward expansion...
Founder Securities: the revenue growth rate of the pharmacy sector slows down, and the concentration is expected to accelerate.
The individual account reform of medical insurance has led to a decrease in personal account income, affecting pharmaceutical sales and pharmacy business relying on individual account payments. In 2023, pharmacy medical insurance personal account expenditures decreased by 9%, and this trend is expected to continue in 2024.
[Brokerage Focus] CMB International maintains a "buy" rating on United Lab (03933), pointing out that short-term revenue from human antibiotics is difficult to increase rapidly.
Jingwu Cai Xun | CITIC International issued a research report, stating that United Lab (03933) achieved a year-on-year revenue growth of 3.9% to 7.176 billion yuan (RMB, hereinafter), with a shareholder's net income increase of 16.1% to 1.49 billion yuan in the first half of the year. The revenue was slightly below expectations, but the profit slightly exceeded expectations. The bank stated that the company's business mainly includes formulations (including human antibiotics, animal medicine, and insulin), intermediates, and active pharmaceutical ingredients. In the first half of 2024, in the formulation sector, some human antibiotic products were affected by centralized procurement, resulting in a slight decline of revenue for this sector by 1.5% year-on-year. However, the bank should note that this sector
Is the chain of pharmacies entering a "mini ice age"? H1 growth rate "downgrades", the industry's high-growth stores may reach turning point.
① The growth rate of sales revenue of all categories in retail pharmacies has slowed down, and the competition in stock continues to intensify. In the first half of this year, it was difficult for major chain pharmacies to increase revenue and profit. ② In the future, the focus of pharmacy competition will shift to commodity extension and services. According to the prediction of Zhongkang Industry Research Institute, the growth rate of pharmaceuticals in all end terminals in 2024 is expected to decrease to 4.9%, a decrease from 2023.
Will you be eliminated if you don't go overseas? In the first half of the year, the proportion of innovative drug outbound business development accounted for about 80% | Industry Dynamics.
①At the 2024 New Investment Conference hosted by Frost Sullivan, the issue of going global was favored by participants. ②There is a new trend in the export of innovative drugs in China, for example, the number of export BDs exceeded License-in for the first time in 2023. ③Some participating experts put forward rational opinions and called for internal strength, not just enthusiasm.
Is United Laboratories International Holdings (HKG:3933) Using Too Much Debt?
No Data
No Data